Fiona Forrestal

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

Stephen Salloway, Spyros Chalkias, Frederik Barkhof et al. · JAMA Neurology · 2021 · 544 citations · Full text

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Zuranolone for the Treatment of Postpartum Depression

Kristina M. Deligiannidis, Samantha Meltzer‐Brody, Bassem Maximos et al. · American Journal of Psychiatry · 2023 · 154 citations

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

Paul O’Connor, Andrew Goodman, Ludwig Kappos et al. · Neurology · 2014 · 134 citations · Full text

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

SA Morrow, PW O'Connor, CH Polman et al. · Multiple Sclerosis Journal · 2010 · 116 citations